Hikma Pharmaceuticals PLC Annual Report 2014 NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS continued 38.
RELATED PARTIES Transactions between the Company and its subsidiaries have been eliminated on consolidation and are not disclosed in this Note.
Transactions between the Group and its associates and other related parties are disclosed below.
Trading transactions: During the year, Group companies entered into the following transactions with related parties: Darhold Limited: is a related party of the Group because it is considered one of the major shareholders of Hikma Pharmaceuticals PLC with an ownership percentage of 28.8% at the end of 2014 2013: 28.9%.
Further details on the relationship between Mr Samih Darwazah, MrSaid Darwazah, Mr Mazen Darwazah and Mr Ali Al-Husry, and Darhold Limited are given in the Directors Report.
Other than dividends as paid to all shareholders, there were no transactions between the Group and Darhold Limited in the year.
Capital Bank Jordan: is a related party of the Group because one Hikma Pharmaceuticals PLC Board member is also a board member of Capital Bank Jordan.
Total cash balances at Capital Bank Jordan were $5.7 million 31 December 2013: $17.2 million.
Facilities granted byCapital Bank to the Group amounted to $nil 31 December 2013: $4.7 million.
Interest expense income is within the market rate.
Arab Bank: is a related party of the Group because one senior management member in Hikma Pharmaceuticals PLC is also a board member ofArab Bank PLC.
Total cash balances at Arab Bank were $90.4 million 31 December 2013: $51.5 million.
Facilities granted by Arab Bank tothe Group amounted to $115.0 million 31 December 2013: $169.4 million.
Jordan International Insurance Company: is a related party of the Group because one board member of the company is also a Board member of Hikma Pharmaceuticals PLC.
Total insurance premiums paid by the Group to Jordan International Insurance Company during the year were $0.1 million 2013: $0.2 million.
The Groups insurance expense for Jordan International Insurance Company contracts in the year 2014 was $0.1 million 2013: $0.4 million.
The amounts due to Jordan International Insurance Company at the year end were $nil 2013: Due to $0.1 million.
Labatec Pharma: is a related party of the Group because it is owned by Mr Samih Darwazah.
During 2014, the Group total sales to Labatec Pharma amounted to $0.5 million 2013: $0.4 million.
At 31 December 2014, the amount owed from Labatec Pharma to the Group was $0.1 million 2013: Owed from $nil.
Jordan Resources & Investments Company: is a related party of the Group because three Board members of the Group are shareholders inthefirm.
During 2014, fees of $nil 2013: $0.2 million were paid for training services provided.
American University of Beirut: is a related party of the Group because one Board member of the Group is also a trustee of the University.
During 2014, fees of $0.1 million 2013: $0.2 million were paid.
At 31 December 2014, the amount owed to American University of Beirut from the Group amounted to $nil 2013: owed $0.1 million.
HikmaCure: the Group held a 50:50 joint venture JV agreement with MIDROC Pharmaceuticals Limited.
The JV is called HikmaCure.
Hikma and MIDROC will invest in HikmaCure in equal proportions and have committed to provide up to $22 million each in cash, of which $2.5 million has been paid in previous periods.
Unimark: the Group held a non-controlling interest of 23.1% in the Indian company Unimark Remedies Limited Unimark at 31 December 2014 31 December 2013: 23.1%.
During 2014, the Group paid an amount of $2.5 million in relation to a products development agreement 31 December 2013: $3.0 million.
Haosun: the Group held a non-controlling interest of 30.1% in Hubei Haosun Pharmaceutical Co. Ltd Haosun at 31 December 2014 31 December 2013: 30.1%.
During 2014, the total purchases from Haosun were $1.0 million 31 December 2013: $0.2 million.
Remuneration of key management personnel The remuneration of the key management personnel comprising the Executive and Non-Executive Directors and certain of senior management as set out in the Directors Report of the Group is set out below in aggregate for each of the categories specified in IAS24Related Party Disclosures.
Further information about the remuneration of the individual Directors is provided in the audited part oftheRemuneration Committee Report on pages 90 to 109.
2014 2013 $m $m Short-term employee benefits 15.7 14.9 Share-based payments 2.4 2.4 Post-employment benefits 0.1 0.2 Other benefits 0.2 0.2 18.4 17.7 162
